Edition:
India

Foamix Pharmaceuticals Ltd (FOMX.OQ)

FOMX.OQ on NASDAQ Stock Exchange Global Market

5.21USD
20 Apr 2018
Change (% chg)

$0.32 (+6.54%)
Prev Close
$4.89
Open
$4.92
Day's High
$5.25
Day's Low
$4.92
Volume
19,586
Avg. Vol
33,824
52-wk High
$7.43
52-wk Low
$4.05

Chart for

About

Foamix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development and commercialization of foam-based formulations, using its technology, which includes its foam platforms. It is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea and... (more)

Overall

Beta: --
Market Cap(Mil.): $241.40
Shares Outstanding(Mil.): 37.43
Dividend: --
Yield (%): --

Financials

BRIEF-Foamix Reports Fiscal Year 2017 Financial Results And Provides Corporate Update

* FOAMIX REPORTS FISCAL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

28 Feb 2018

BRIEF-Tamarkin Medical Reports 7.3 Percent Passive Stake In Foamix Pharmaceuticals

* TAMARKIN MEDICAL INNOVATIONS LTD REPORTS 7.3 PERCENT PASSIVE STAKE IN FOAMIX PHARMACEUTICALS AS OF DECEMBER 31, 2017 - SEC FILING Source text: (http://bit.ly/2so9g8s) Further company coverage:

14 Feb 2018

BRIEF-Foamix Announces Positive Results From Late Stage Acne Treatment Study

* FOAMIX ANNOUNCES POSITIVE RESULTS FROM PHASE 3 OPEN-LABEL SAFETY EXTENSION EVALUATING FMX-101 TOPICAL MINOCYCLINE FOAM FOR TREATMENT UP TO 1 YEAR Source text for Eikon: Further company coverage:

04 Jan 2018

BRIEF-Foamix Names David Domzalski As A Member Of Company Board

* FOAMIX NAMES MR. DAVID DOMZALSKI AS A MEMBER OF THE BOARD OF FOAMIX PHARMACEUTICALS

03 Jan 2018

BRIEF-Foamix Q3 loss per share $0.47

* Foamix reports third quarter 2017 financial results and provides business update

15 Nov 2017

Earnings vs. Estimates